• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真实世界风湿病学注册研究联盟:德国风湿病数据风湿病端口(RHADAR)注册。

A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry.

机构信息

Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany.

Medizinische Klinik 3, Rheumatology/Immunology, Universitätsklinik Würzburg, Würzburg, Germany.

出版信息

J Med Internet Res. 2021 May 20;23(5):e28164. doi: 10.2196/28164.

DOI:10.2196/28164
PMID:34014170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8176344/
Abstract

Real-world data are crucial to continuously improve the management of patients with rheumatic and musculoskeletal diseases (RMDs). The German RheumaDatenRhePort (RHADAR) registry encompasses a network of rheumatologists and researchers in Germany providing pseudonymized real-world patient data and allowing timely and continuous improvement in the care of RMD patients. The RHADAR modules allow automated anamnesis and adaptive coordination of appointments regarding individual urgency levels. Further modules focus on the collection and integration of electronic patient-reported outcomes in between consultations. The digital RHADAR modules ultimately allow a patient-centered adaptive approach to integrated medical care starting as early as possible in the disease course. Such a closed-loop system consisting of various modules along the whole patient pathway enables comprehensive and timely patient management in an unprecedented manner.

摘要

真实世界的数据对于不断改善风湿和肌肉骨骼疾病(RMDs)患者的管理至关重要。德国 RheumaDatenRhePort(RHADAR)登记处由德国的风湿病学家和研究人员组成的网络,提供匿名的真实世界患者数据,并允许及时和持续改进 RMD 患者的护理。RHADAR 模块允许对病史进行自动记录,并根据个人紧急程度自动协调预约。进一步的模块侧重于在咨询之间收集和整合电子患者报告的结果。最终,数字化的 RHADAR 模块允许在疾病过程中尽早开始采用以患者为中心的自适应方法,实现综合医疗服务。这种由沿着整个患者路径的各种模块组成的闭环系统,以前所未有的方式实现了全面和及时的患者管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/55963fb39702/jmir_v23i5e28164_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/b57a69d40e85/jmir_v23i5e28164_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/61e077eeca92/jmir_v23i5e28164_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/6ab52d463387/jmir_v23i5e28164_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/270e19ef9d94/jmir_v23i5e28164_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/55963fb39702/jmir_v23i5e28164_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/b57a69d40e85/jmir_v23i5e28164_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/61e077eeca92/jmir_v23i5e28164_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/6ab52d463387/jmir_v23i5e28164_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/270e19ef9d94/jmir_v23i5e28164_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f560/8176344/55963fb39702/jmir_v23i5e28164_fig5.jpg

相似文献

1
A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry.真实世界风湿病学注册研究联盟:德国风湿病数据风湿病端口(RHADAR)注册。
J Med Internet Res. 2021 May 20;23(5):e28164. doi: 10.2196/28164.
2
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases.风湿病学实践中的全球挑战与机遇:风湿和肌肉骨骼疾病世界论坛白皮书
Clin Rheumatol. 2015 May;34(5):819-29. doi: 10.1007/s10067-014-2841-6. Epub 2014 Dec 14.
3
Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).风湿和肌肉骨骼疾病(RMDs)术语的通用语言描述,用于与普通公众、医疗保健提供者和其他利益相关者进行沟通,该描述得到了欧洲抗风湿病联盟(EULAR)和美国风湿病学会(ACR)的认可。
Arthritis Rheumatol. 2018 Jun;70(6):826-831. doi: 10.1002/art.40448. Epub 2018 Mar 13.
4
A global perspective on the challenges and opportunities in learning about rheumatic and musculoskeletal diseases in undergraduate medical education : White paper by the World Forum on Rheumatic and Musculoskeletal Diseases (WFRMD).全球视角下本科医学教育中学习风湿和肌肉骨骼疾病的挑战和机遇:风湿和肌肉骨骼疾病世界论坛(WFRMD)白皮书。
Clin Rheumatol. 2020 Mar;39(3):627-642. doi: 10.1007/s10067-019-04544-y. Epub 2019 May 24.
5
Evidence for telemedicine heterogeneity in rheumatic and musculoskeletal diseases care: a scoping review.评估远程医疗在风湿和肌肉骨骼疾病治疗中的异质性:系统综述。
Clin Rheumatol. 2024 Sep;43(9):2721-2763. doi: 10.1007/s10067-024-07052-w. Epub 2024 Jul 10.
6
[Memorandum of the German Society for Rheumatology on the quality of treatment in rheumatology - Update 2016].[德国风湿病学会关于风湿病治疗质量的备忘录 - 2016年更新]
Z Rheumatol. 2017 Apr;76(3):195-207. doi: 10.1007/s00393-017-0297-1.
7
Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).风湿和肌肉骨骼疾病(RMDs)术语的通用语言描述,用于与普通公众、医疗保健提供者和其他利益相关者进行沟通,该描述得到了欧洲抗风湿病联盟(EULAR)和美国风湿病学会(ACR)的认可。
Ann Rheum Dis. 2018 Jun;77(6):829-832. doi: 10.1136/annrheumdis-2017-212565. Epub 2018 Mar 13.
8
[Treat to participation : Position paper of the German Society for Rheumatology on sustained improvement of functional health of patients with rheumatic and musculoskeletal diseases].[参与治疗:德国风湿病学会关于持续改善风湿性和肌肉骨骼疾病患者功能健康的立场文件]
Z Rheumatol. 2015 Aug;74(6):553-7. doi: 10.1007/s00393-015-1640-z.
9
COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19).意大利风湿病学 COVID-19 :意大利风湿病学会(CONTROL-19)意大利登记处的初步结果。
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. Epub 2020 Jul 28.
10
Opportunities and Barriers of Telemedicine in Rheumatology: A Participatory, Mixed-Methods Study.远程医疗在风湿病学中的机遇与挑战:一项参与式、混合方法研究。
Int J Environ Res Public Health. 2021 Dec 13;18(24):13127. doi: 10.3390/ijerph182413127.

引用本文的文献

1
Discordance between patient and physician reported global disease activity in PsA is associated with mental health-a cross-sectional analysis.银屑病关节炎患者与医生报告的整体疾病活动度之间的不一致与心理健康相关——一项横断面分析。
Rheumatol Int. 2025 Aug 5;45(8):181. doi: 10.1007/s00296-025-05933-0.
2
Potentials and barriers of digital patient education in rheumatic disease management: an exploratory qualitative interview study.数字患者教育在风湿病管理中的潜力与障碍:一项探索性定性访谈研究
Rheumatol Int. 2025 Jun 4;45(6):148. doi: 10.1007/s00296-025-05893-5.
3
RhePort 1.3 enhances early identification of inflammatory rheumatic diseases: a prospective study in German rheumatology settings.

本文引用的文献

1
Digital rheumatology in the era of COVID-19: results of a national patient and physician survey.COVID-19 时代的数字风湿病学:一项全国患者和医生调查结果。
RMD Open. 2021 Feb;7(1). doi: 10.1136/rmdopen-2020-001548.
2
Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower.哪些患者报告结局对风湿病患者的数字化追踪很重要?关节炎力量(ArthritisPower)中的真实世界纵向研究。
Arthritis Res Ther. 2021 Feb 10;23(1):53. doi: 10.1186/s13075-021-02430-0.
3
Google search data as a novel adjunct to patient and public involvement in rheumatology research.
RhePort 1.3 增强了对炎性风湿性疾病的早期识别:一项在德国风湿病诊疗环境中的前瞻性研究。
Rheumatol Int. 2025 Apr 28;45(5):129. doi: 10.1007/s00296-025-05861-z.
4
Janus kinase inhibitors show a longer drug survival than biologics in a real-world cohort of patients with rheumatoid arthritis - a retrospective analysis from the RHADAR database.在类风湿性关节炎患者的真实世界队列中,Janus激酶抑制剂比生物制剂具有更长的药物生存期——来自RHADAR数据库的一项回顾性分析。
Rheumatol Int. 2025 Apr 15;45(5):100. doi: 10.1007/s00296-025-05859-7.
5
Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study.在欧洲药品管理局安全建议前后使用 Janus 激酶抑制剂:一项回顾性研究。
Front Immunol. 2024 Aug 22;15:1445680. doi: 10.3389/fimmu.2024.1445680. eCollection 2024.
6
Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.真实世界队列中轴性脊柱关节炎患者中与肿瘤坏死因子抑制剂相比,Janus 激酶抑制剂和白细胞介素-17 抑制剂药物生存时间更短的分析 - RHADAR 网络的回顾性分析。
Rheumatol Int. 2024 Oct;44(10):2057-2066. doi: 10.1007/s00296-024-05671-9. Epub 2024 Aug 13.
7
Diagnostic Accuracy of a Mobile AI-Based Symptom Checker and a Web-Based Self-Referral Tool in Rheumatology: Multicenter Randomized Controlled Trial.移动人工智能症状检查器和基于网络的自我转诊工具在风湿病学中的诊断准确性:多中心随机对照试验。
J Med Internet Res. 2024 Jul 23;26:e55542. doi: 10.2196/55542.
8
Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database.德国门诊中银屑病关节炎患者中肿瘤坏死因子抑制剂和白细胞介素-17 抑制剂相对于 Janus 激酶抑制剂和白细胞介素-12/23 抑制剂的药物生存优势:RHADAR 数据库的回顾性分析。
Front Immunol. 2024 May 23;15:1395968. doi: 10.3389/fimmu.2024.1395968. eCollection 2024.
9
"" Levers for the Sustained Employment of Patients with Chronic Inflammatory Arthritis: A French Qualitative Study.慢性炎症性关节炎患者持续就业的杠杆:一项法国定性研究。
Int J Environ Res Public Health. 2022 Nov 7;19(21):14616. doi: 10.3390/ijerph192114616.
10
Digitally-supported patient-centered asynchronous outpatient follow-up in rheumatoid arthritis - an explorative qualitative study.数字化支持的以患者为中心的类风湿关节炎门诊随访 - 探索性定性研究。
BMC Health Serv Res. 2022 Oct 28;22(1):1297. doi: 10.1186/s12913-022-08619-6.
谷歌搜索数据在风湿病学研究中作为一种新颖的辅助手段,用于患者和公众的参与。
Rheumatol Int. 2021 Apr;41(4):771-779. doi: 10.1007/s00296-020-04723-0. Epub 2020 Oct 19.
4
Public interest in rheumatic diseases and rheumatologist in the United States during the COVID-19 pandemic: evidence from Google Trends.美国在 COVID-19 大流行期间对风湿性疾病和风湿病学家的公众关注度:来自谷歌趋势的证据。
Rheumatol Int. 2021 Feb;41(2):329-334. doi: 10.1007/s00296-020-04728-9. Epub 2020 Oct 18.
5
[Current state, goals and quality standards of outpatient care in rheumatology: position paper of the Professional Association of German Rheumatologists (BDRh)].[风湿病门诊护理的现状、目标及质量标准:德国风湿病学家专业协会(BDRh)立场文件]
Z Rheumatol. 2020 Oct;79(8):770-779. doi: 10.1007/s00393-020-00872-6. Epub 2020 Sep 14.
6
Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa.在线自我转诊工具与基于医生的转诊策略比较,以早期识别轴向脊柱关节炎高概率患者。
Semin Arthritis Rheum. 2020 Oct;50(5):1015-1021. doi: 10.1016/j.semarthrit.2020.07.018. Epub 2020 Sep 7.
7
Mobile Health Usage, Preferences, Barriers, and eHealth Literacy in Rheumatology: Patient Survey Study.移动医疗的使用、偏好、障碍和风湿病患者的电子健康素养:患者调查研究。
JMIR Mhealth Uhealth. 2020 Aug 12;8(8):e19661. doi: 10.2196/19661.
8
[Position paper of the commission on digital rheumatology of the German Society of Rheumatology: tasks, targets and perspectives for a modern rheumatology].[德国风湿病学会数字风湿病学委员会立场文件:现代风湿病学的任务、目标与前景]
Z Rheumatol. 2020 Aug;79(6):562-569. doi: 10.1007/s00393-020-00834-y.
9
Digital crowdsourcing: unleashing its power in rheumatology.数字众包:在风湿病学中的应用。
Ann Rheum Dis. 2020 Sep;79(9):1139-1140. doi: 10.1136/annrheumdis-2020-217697. Epub 2020 Jun 11.
10
Acceptance, Usage, and Barriers of Electronic Patient-Reported Outcomes Among German Rheumatologists: Survey Study.德国风湿病学家对电子患者报告结局的接受度、使用情况和障碍:调查研究。
JMIR Mhealth Uhealth. 2020 Jul 20;8(7):e18117. doi: 10.2196/18117.